跳至主要内容
临床试验/NCT03503734
NCT03503734已完成不适用

Integrated Care for Migraine and Chronic Tension-type Headaches

Universität Duisburg-Essen1 个研究点 分布在 1 个国家目标入组 158 人开始时间: 2011年8月18日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
158
试验地点
1
主要终点
Headache frequency

研究概览

简要总结

Chronic headache is among the most common neurological disorders with major physical, psychological, social and economic impact. The aim of this prospective observational study isto investigate the effects of an interdisciplinary multimodal integrated care program in patients with chronic migraine and/or tension-type headache.

158 patients with chronic migraine or tensions-type headache at least five days per month for at least 6 months and current intake of triptans (migraine) or analgesic drugs (tension-type headache) are eligible. Patients undergo inpatient, outpatient and/or semi-stationary treatment including conventional headache diagnostics and therapy as well as traditional Chinese medicine, European naturopathy, and mind-body-medicine approaches. Headache frequency is defined as the primary outcome; secondary outcomes include pain (visual analog scale, Pain Perception Scale), triptans and analgesics use (headache diary), health-related quality of life (SF-36), function (Headache Disability Inventory, Patient-specific Functional Scale), depression and anxiety (Hospital Anxiety and Depression Scale), and pain self-efficacy (Pain Self-Efficacy Questionnaire). Outcomes are assessed at treatment start, treatment end and 6 months after treatment end.

详细描述

Chronic headache is among the most common neurological disorders with major physical, psychological, social and economic impact. The aim of this prospective observational study isto investigate the effects of an interdisciplinary multimodal integrated care program in patients with chronic migraine and/or tension-type headache.

158 patients with chronic migraine or tensions-type headache at least five days per month for at least 6 months and current intake of triptans (migraine) or analgesic drugs (tension-type headache) are eligible. Patients undergo inpatient, outpatient and/or semi-stationary treatment including conventional headache diagnostics and therapy as well as traditional Chinese medicine, European naturopathy, and mind-body-medicine approaches. Headache frequency is defined as the primary outcome; secondary outcomes include pain (visual analog scale, Pain Perception Scale), triptans and analgesics use (headache diary), health-related quality of life (SF-36), function (Headache Disability Inventory, Patient-specific Functional Scale), depression and anxiety (Hospital Anxiety and Depression Scale), and pain self-efficacy (Pain Self-Efficacy Questionnaire). Outcomes are assessed at treatment start, treatment end and 6 months after treatment end.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • headache at least five days per month for at least 6 months current intake of a) at least 10 triptans per month or b) analgesic drugs that can themselves elicit headache

排除标准

  • 未提供

结局指标

主要结局

Headache frequency

时间窗: Treatment end, an average of 5 months

Headache days/month

次要结局

  • Pain perception(6 months after treatment end)
  • Function(6 months after treatment end)
  • Pain bothersomeness(6 months after treatment end)
  • Headache frequency(6 months after treatment end)
  • Self-Efficacy(6 months after treatment end)
  • Pain intensity(6 months after treatment end)
  • Quality of life(6 months after treatment end)
  • Headache Disability(6 months after treatment end)
  • Anxiety/Depression Scale(6 months after treatment end)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Holger Cramer

Research Director

Universität Duisburg-Essen

研究点 (1)

Loading locations...

相似试验